Tumor Necrosis Factor-α Inhibitor Use Is Not Associated with Lipid Changes in Rheumatoid Arthritis

REFERENCES

1. 1.↵
   1. Wasko MC

   . Rheumatoid arthritis and cardiovascular disease. Curr Rheumatol Rep 2008;10:390–7.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Toms TE,
   2. Symmons DP,
   3. Kitas GD

   . Dyslipidaemia in rheumatoid arthritis: The role of inflammation, drugs, lifestyle and genetic factors. Curr Vasc Pharmacol 2010;8:301–26.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Nishida K,
   2. Okada Y,
   3. Nawata M,
   4. Saito K,
   5. Tanaka Y

   . Induction of hyperadiponectinemia following long-term treatment of patients with rheumatoid arthritis with infliximab (IFX), an anti-TNF-alpha antibody. Endocr J 2008;55:213–6.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Popa C,
   2. van den Hoogen FH,
   3. Radstake TR,
   4. Netea MG,
   5. Eijsbouts AE,
   6. den Heijer M,
   7. et al.

   Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis. Ann Rheum Dis 2007;66:1503–7.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   1. Peters MJ,
   2. Vis M,
   3. van Halm VP,
   4. Wolbink GJ,
   5. Voskuyl AE,
   6. Lems WF,
   7. et al.

   Changes in lipid profile during infliximab and corticosteroid treatment in rheumatoid arthritis. Ann Rheum Dis 2007;66:958–61.

   OpenUrlAbstract/FREE Full Text
6. 6.↵
   1. Saiki O,
   2. Takao R,
   3. Naruse Y,
   4. Kuhara M,
   5. Imai S,
   6. Uda H

   . Infliximab but not methotrexate induces extra-high levels of VLDL-triglyceride in patients with rheumatoid arthritis. J Rheumatol 2007;34:1997–2004.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   1. Tam LS,
   2. Tomlinson B,
   3. Chu TT,
   4. Li TK,
   5. Li EK

   . Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis. Clin Rheumatol 2007;26:1495–8.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Allanore Y,
   2. Kahan A,
   3. Sellam J,
   4. Ekindjian OG,
   5. Borderie D

   . Effects of repeated infliximab therapy on serum lipid profile in patients with refractory rheumatoid arthritis. Clin Chim Acta 2006;365:143–8.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Dahlqvist SR,
   2. Engstrand S,
   3. Berglin E,
   4. Johnson O

   . Conversion towards an atherogenic lipid profile in rheumatoid arthritis patients during long-term infliximab therapy. Scand J Rheumatol 2006;35:107–11.

   OpenUrlCrossRefPubMed
10. 10.↵
    1. Kiortsis DN,
    2. Mavridis AK,
    3. Filippatos TD,
    4. Vasakos S,
    5. Nikas SN,
    6. Drosos AA

    . Effects of infliximab treatment on lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis. J Rheumatol 2006;33:921–3.

    OpenUrlAbstract/FREE Full Text
11. 11.↵
    1. Spanakis E,
    2. Sidiropoulos P,
    3. Papadakis J,
    4. Ganotakis E,
    5. Katsikas G,
    6. Karvounaris S,
    7. et al.

    Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab. J Rheumatol 2006;33:2440–6.

    OpenUrlAbstract/FREE Full Text
12. 12.↵
    1. Vis M,
    2. Nurmohamed MT,
    3. Wolbink G,
    4. Voskuyl AE,
    5. de Koning M,
    6. van de Stadt R,
    7. et al.

    Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis. J Rheumatol 2005;32:252–5.

    OpenUrlAbstract/FREE Full Text
13. 13.↵
    1. Yazici Y,
    2. Krasnokutsky S,
    3. Barnes JP,
    4. Hines PL,
    5. Wang J,
    6. Rosenblatt L

    . Changing patterns of tumor necrosis factor inhibitor use in 9074 patients with rheumatoid arthritis. J Rheumatol 2009;36:907–13.

    OpenUrlAbstract/FREE Full Text
14. 14.↵
    1. Soubrier M,
    2. Jouanel P,
    3. Mathieu S,
    4. Poujol D,
    5. Claus D,
    6. Dubost JJ,
    7. et al.

    Effects of anti-tumor necrosis factor therapy on lipid profile in patients with rheumatoid arthritis. Joint Bone Spine 2008;75:22–4.

    OpenUrlCrossRefPubMed
15. 15.↵
    1. Seriolo B,
    2. Paolino S,
    3. Ferrone C,
    4. Cutolo M

    . Effects of etanercept or infliximab treatment on lipid profile and insulin resistance in patients with refractory rheumatoid arthritis. Clin Rheumatol 2007;26:1799–800.

    OpenUrlCrossRefPubMed
16. 16.↵
    1. Garces SP,
    2. Parreira Santos MJ,
    3. Vinagre FM,
    4. Roque RM,
    5. da Silva JA

    . Anti-tumour necrosis factor agents and lipid profile: A class effect?. Ann Rheum Dis 2008;67:895–6.

    OpenUrlFREE Full Text
17. 17.↵
    1. Shai I,
    2. Rimm EB,
    3. Hankinson SE,
    4. Curhan G,
    5. Manson JE,
    6. Rifai N,
    7. et al.

    Multivariate assessment of lipid parameters as predictors of coronary heart disease among postmenopausal women: Potential implications for clinical guidelines. Circulation 2004;110:2824–30.

    OpenUrlAbstract/FREE Full Text
18. 18.↵
    1. Meyer JW,
    2. Schultz JS,
    3. O’Donnell JC,
    4. Patel PA,
    5. Sasane RM

    . Patterns and effectiveness of lipid-lowering therapies in a managed care environment. Value Health 2005;8:601–12.

    OpenUrlCrossRefPubMed